Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Nine months ended March 31, 2025 (Fiscal Year 2025)
Business Overview: A development-stage biopharmaceutical company focused on cancer treatments, specifically its lead product candidate PRP (a pro-enzyme formulation). The company has no commercial revenue and relies on financing to fund research and development (R&D).
Recent Corporate Action: A 1:60,000 reverse stock split became effective on January 29, 2025. All share data in this filing has been retroactively adjusted.
Key Financial Metrics
| Metric | Nine Months Ended March 31, 2025 |
Nine Months Ended March 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(54,851,839) | $(1,461,950) |
| Net Loss Per Share (Basic & Diluted) | $(38.62) | $(3,164.41) |
| Cash and Cash Equivalents (Ending) | $50,760 | $6,222 |
| Total Assets | $22,527,352 | $72,365 |
| Total Liabilities | $4,435,060 | $3,851,424 |
| Stockholders' Equity | $18,092,292 | $(3,779,059) |
| Net Cash Used in Operating Activities | $(377,982) | $(675,152) |
| Net Cash Provided by Financing Activities | $483,000 | $690,920 |
Material Changes vs. Prior Period
- Explosive Increase in Net Loss: Net loss surged from $1.46 million to $54.85 million. This is primarily driven by a non-cash stock-based compensation expense of approximately $52.85 million (issuance of shares for services and prepaid services).
- Balance Sheet Transformation: Total assets increased from $72,365 to $22.5 million. This increase is almost entirely due to the capitalization of prepaid expenses ($22.38 million) resulting from the issuance of common stock for future consulting and advisory services.
- Equity Position: Stockholders' equity swung from a deficit of $3.78 million to a positive balance of $18.09 million, driven by the issuance of shares for services and debt conversions.
- Debt Defaults: As of March 31, 2025, the company is in default on multiple convertible notes and promissory notes with a total principal amount of approximately $275,485, plus additional past-due loans.
Outlook, Risks, and Management Commentary
- Going Concern: Management explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern for the next 12 months. The company has no revenue, an accumulated deficit of $121.55 million, and insufficient cash to meet obligations.
- Liquidity Strategy: The company is actively seeking additional financing through equity or debt issuances. It recently filed an S-1 registration statement for an underwritten offering and applied for Nasdaq Capital Market listing.
- Debt Restructuring: The company has been settling debt through the issuance of common stock (Debt Exchange Agreements) rather than cash, resulting in significant losses on extinguishment of debt ($840,032 for the nine months).
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including lack of written documentation, insufficient segregation of duties, and lack of an audit committee.
- R&D Status: R&D expenses decreased slightly ($170k vs $196k) due to cost-cutting measures. The company is negotiating further collaborations with the University of Jaén.
Investor Verification Checklist
- Stock-Based Compensation Validity: Verify the valuation and terms of the $52.85 million in stock-based compensation issued for services. Confirm the fair value of shares issued for "prepaid services" and the likelihood of those services being rendered.
- Debt Default Status: Confirm the current status of negotiations with lenders regarding the defaulted notes (principal ~$275k) and the risk of acceleration or litigation.
- Going Concern Mitigation: Assess the probability of the proposed S-1 offering closing and the company's ability to raise sufficient capital to fund operations beyond the current cash balance of $50,760.
- Reverse Split Impact: Review the post-split share count (11.6 million shares) and the impact on liquidity and trading status on the OTC/Nasdaq.
- Related Party Transactions: Scrutinize the loans and lease agreements with related parties (e.g., North Horizon Pty Ltd., Josef Zelinger) and the terms of debt exchanges with former directors.